Actavis has received approval from the US Food and Drug Administration to market alprazolam ER tablets. Distribution of the product will commence in coming weeks.
Alprazolam ER tablets, the generic equivalent of Pfizer's Xanax XR tablets, will be available in 0.5 mg, 1 mg, 2 mg, and 3 mg strengths. Alprazolam ER tablets are indicated for the treatment of anxiety and panic disorder.
Annual sales of alprazolam ER tablets in the US were approximately US $53.9 million for the twelve months ending December 2006 according to IMS Health data.